Kenox Pharmaceuticals and Lactiga US are collaborating to develop mucosal-targeted secretory IgA therapies for immunodeficient individuals, supported by a grant from the National Institute of Allergy and Infectious Diseases. The partnership aims to enhance immunity and advance nasal and inhaled pharma development.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing